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ABSTRACT 
Fidaxomicin is a macrocyclic antibiotic licensed for treating Clostridium difficile 
infection (CDI). In the UK, fidaxomicin is often reserved for severe CDI or 
recurrences. At Queen Elizabeth Hospital Birmingham, all courses of fidaxomicin 
during 2017/18 were reviewed. Thirty-eight patients received fidaxomicin, of which 
64% patients responded to treatment when fidaxomicin was given during the first 
episode of a mild CDI. Conversely, all patients with recurrent CDI (rCDI) failed 
treatment with fidaxomicin. There were mixed results with using fidaxomicin for 
severe CDI, with only 42% of patients responding. Our results suggest fidaxomicin is 
best suited as a treatment for mild CDI during a patient’s first episode. 
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INTRODUCTION 
Clostridium difficile infection (CDI) causes a range of symptoms from mild diarrhoea 
to life threatening pseudomembranous colitis.1-4 The majority of patients experience 
a single episode of infection, however, despite treatment, some develop further 
episodes termed rCDI.1 It is estimated that, following initial resolution of symptoms, 
rCDI occurs in 20%–30% of patients. Fidaxomicin is a macrocyclic antibiotic licensed 
for treating CDI. Fidaxomicin has been shown to have comparable clinical cure when 
compared to vancomycin.1-2 In the UK, vancomycin and fidaxomicin are generally 
reserved for severe CDI or for subsequent recurrences.5 There are limited data on 
fidaxomicin and its effect/usefulness in the treatment of rCDI and severe CDI.5 
Recently, Enoch et al reviewed all episodes of fidaxomicin use at an English hospital 
in order to assess patient outcome data.5 They described fidaxomicin use in 15 
patients with rCDI, concluding that, although fidaxomicin was well tolerated, the utility 
of fidaxomicin at this stage of infection is unclear.5 At QEHB, our treatment algorithm 
includes first line therapy with metronidazole for patients with mild to moderate CDI, 
vancomycin for relapsed or severe CDI, followed by fidaxomicin in the event of 
treatment failure or faecal microbiota transplant (FMT) after two recurrences/ 
treatment failures.6 During 2017/18, 38 patients received fidaxomicin for CDI at 
QEHB. Similar to Enoch et al we reviewed all episodes of fidaxomicin prescription in 
order to assess patient outcome data.5 
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METHODS 
Setting. Queen Elizabeth Hospital Birmingham (QEHB), part of University Hospitals 
Birmingham (UHB) NHS Foundation Trust is a tertiary referral teaching hospital in 
Birmingham, UK that provides clinical services to over one million patients every 
year.  
C. difficile testing. In line with national guidance, an algorithmic approach to 
identifying CDI is undertaken at QEHB.4,7-9 A three-stage algorithm is employed.7-9 
Briefly, any patient with ≥1 episode of unexplained diarrhoea has their faecal 
specimen tested for CDI. The CDI testing algorithm consists of an initial screening 
step using a Premier GDH EIA (Meridian Bioscience, Cincinnati, Ohio), followed by a 
NAAT (Cepheid, XpertTM C. difficile, US) for GDH positive samples only.7 All samples 
testing GDH and NAAT positive have a Premier Toxins A and B EIA (Meridian 
Bioscience, Cincinnati, Ohio).7 
Study design and definitions. We carried out a single centre observational 
retrospective cohort study where all patients aged ≥18 years commenced on 
fidaxomicin during April 2017 to March 2018 were reviewed for clinical response to 
CDI treatment. All 38 patients who were positive by GDH and NAAT, and treated 
with fidaxomicin, between April 2017 to March 2018 were included in the study. We 
analysed the Bristol Stool Chart (BSC) and clinical features, based on the daily 
assessment infection severity tool (DAISY) as previously described.6 The DAISY tool 
was also used to define mild, mild/moderate and severe forms of CDI.6 In addition, 
we collected details of the outcome of the patients (at end of therapy and, at 30 and 
90 days post-cessation of therapy: resolution of diarrhoea, ongoing diarrhoea or 
death). Time until diarrhoea resolution was defined as per Enoch et al.5 
Recurrent CDI. Recurrent CDI was defined as the return of diarrhoea (≥1 episode of 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 5
unexplained diarrhoea) within 28 days of a previous CDI episode and the presence 
of a positive test result for toxigenic C. difficile by GDH and NAAT.6-7 
Treatment failure. Was defined as cases where failure to respond to treatment 
resulted in a change of CDI therapy of the patient.9-10  
Clinical data collection. Patient data collected at the time of a positive result included: 
patient demographics (age, sex), markers of CDI severity (white cell count, C-
reactive protein, serum creatinine, serum albumin, temperature, stool frequency) and 
mortality (one month and 3-month all-cause mortality). 
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RESULTS 
Fidaxomicin treatment. During 2017/18, there were 356 toxin positive results 
occurring in 293 patients. Twenty one percent of these patients had more than one 
positive toxin result, including 10 patients who had 3 or more positive toxin results. 
All 38 patients treated with fidaxomicin received the recommended course of 200mg 
twice daily administered orally for 10 days. Treatment failure with fidaxomicin was 
declared after the recommended course and duration. Sixteen patients had mild to 
moderate CDI, 12 had severe CDI and 10 had rCDI (Table I); no patients received 
fidaxomicin as first line therapy. Whereas the response rates to fidaxomicin in 
patients with mild to moderate and severe CDI were 63% and 42%, respectively, no 
patient with rCDI responded. The recurrent CDI patients were prescribed fidaxomicin 
on average 4.3 months after their first CDI (fidaxomicin prescription ranging 1 to 10 
months after the first CDI episode). Five of the rCDI patients had mild symptoms, 4 
had mild/moderate CDI with 1 having severe CDI. Fidaxomicin was well tolerated 
with no adverse effects documented for any patient. 
First episode of C. difficile. Twenty of the 38 patients received fidaxomicin during 
their first episode of CDI where symptoms did not resolve on first line treatment with 
metronidazole and/or vancomycin. Eleven of the patients received metronidazole as 
first line treatment, which was escalated to vancomycin. Eleven (55%) of these 20 
patients responded to fidaxomicin (Table I). Time to resolution of symptoms ranged 
from 4-10 days (median 8 days). Patients with mild to moderate CDI were more likely 
to respond than patients with severe disease (64% versus 33%). Ten of the 11 
patients who responded remained symptom-free at 90 days (the other patient died 
60 days after completing therapy of reasons unrelated to CDI). 
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DISCUSSION 
Overall, our work confirms the findings of Enoch et al that there was a poor outcome 
for patients with rCDI treated with fidaxomicin.5 In our patient population, all patients 
with rCDI failed treatment with fidaxomicin, whereas Enoch et al reported a 50% 
failure rate.5 Our results suggest fidaxomicin is best suited as a treatment for a mild 
CDI during a patients first episode rather than current UK guidance suggesting for 
use for severe or rCDI.10 Likewise, a recent systematic review by Bienortas et al 
suggested that fidaxomicin frequently provides a sustained cure for non-multiple 
recurrent infections of CDI compared with vancomycin.11 This is not surprising, as 
fidaxomicin may persist on C. difficile spores, whereas vancomycin does not.12 This 
persistence could prevent subsequent growth and toxin production in vitro; having 
implications on spore viability, thereby impacting rCDI rates.12 Current guidelines 
suggest that vancomycin and fidaxomicin are of equal efficacy for treating first 
recurrences of CDI.10 They recommend oral vancomycin or fidaxomicin for second 
(or subsequent) recurrences of CDI, citing evidence from Cornely et al and Louie et 
al where success was seen using fidaxomicin to treat rCDI.13-14 This is in contrast to 
our data, and those of Enoch et al.5 Confounders cannot be ruled out as a reason for 
these discrepancies, and further work with larger numbers of patients is needed; 
however we note that none of the rCDI patients in our study were 
immunosuppressed. We have previously reported a lower rCDI rate (16%) than the 
national average of 25%, and suggested that this may be due to the novel ways of 
managing CDI on our hospital.6 In particular, our use of a daily assessment of 
infection severity tool to monitor patients CDI progression and tailor CDI treatment 
accordingly may select for a particularly recalcitrant group of rCDI patients.6  
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In conclusion, our experience, and that of Enoch et al,5 supports the use of faecal 
microbiota transplantation for the treatment of rCDI as per the recent joint British 
Society of Gastroenterology and Healthcare Infection Society guidance.15 We have 
reported up to 90% success rate of treating rCDI with FMT.7 With the cost of a 10-
day course of fidaxomicin being around £1350, compared with £650 for FMT, we 
suggest that fidaxomicin should mainly be be considered as a treatment option for 
non-multiply recurrent CDI. 
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Table I. Treatment outcomes at the end of 30 days with patients treated at QEHB with Fidaxomicin in 2017/18. 
 
 
 
 
 
 
 
 
NB. * of these 5 patients had mild CDI, 4 patients had mild/moderate CDI and 1 patient had severe CDI. 
 
 All treatment Treated within first episode 
 Responded Failed Total Percentage Responded Failed Total Percentage 
Mild 10 6 16 63 9 5 14 64 
Severe 5 7 12 42 2 4 6 33 
rCDI* 0 10 10 0  -  -  -  - 
Total 15 23 38 39 11 9 20 55 
